Một kháng thể chống lại RANKL trong điều trị loãng xương, bệnh xương viêm và bệnh ác tính

Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell, 93(2): 165–176, 1998 Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 95(7): 3597–3602, 1998 Burgess TL, Qian Y, Kaufman S, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol, 145(3): 527–538, 1999 Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res, 16(2): 348–360, 2001 Bucay N, Sarosi I, Dunstan CR, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev, 12(9): 1260–1268, 1998 Rauner M, Sipos W, Pietschmann P. Osteoimmunology. Int Arch Allergy Immunol, 143(1): 31–48, 2007 Kong YY, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature, 402(6759): 304–309, 1999 Romas E, Sims NA, Hards DK, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol, 161(4): 1419–1427, 2002 Haynes DR, Crotti TN, Loric M, et al. Osteoprotegerin and receptor activator of nuclear factor kappa B ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford), 40(6): 623–630, 2001 Body J. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer, 97(3 Suppl): 859–865, 2003 Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology, 140(10): 4451–4458, 1999 Mancino AT, Klimberg VS, Yamamoto M, et al. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells. J Surg Res, 100(1): 18–24, 2001 Kitazawa S, Kitazawa R. RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol, 198(2): 228–236, 2002 Brown JM, Corey E, Lee ZD, et al. Osteoprotegerin and rank ligand expression in prostate cancer. Urology, 57(4): 611–616, 2001 Zhang J, Dai J, Qi Y, et al. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest, 107(10): 1235–1244, 2001 Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer, 97(3 Suppl): 887–892, 2003 Sezer O, Heider U, Zavrski I, et al. RANK ligand and osteoprotegerin in myeloma bone disease. Blood, 101(6): 2094–2098, 2003 Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature, 423(6937): 337–342, 2003 McClung MR, Lewiecki EM, Cohen SB, et al.; AMG 162 Bone Loss Study Group. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med, 354: 821–831, 2006 Ellis GK, Bone HG, Chlebowski R, et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol, 26(30): 4875–4882, 2008 Sipos W, Pietschmann P, Rauner M, et al. Pathophysiology of osteoporosis. Wien Med Wochenschr, 159(9–10): 230–234, 2009 Schiller C, Gruber R, Redlich K, et al. 17Beta-estradiol antagonizes effects of 1alpha,25-dihydroxyvitamin D3 on interleukin-6 production and osteoclast-like cell formation in mouse bone marrow primary cultures. Endocrinology, 138(11): 4567–4571, 1997 Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet, 359(9319): 761–1767, 2002 Dimai HP, Pietschmann P, Resch H, et al. Österreichischer Leitfaden zur medikamentösen Therapie der postmenopausalen Osteoporose – Update 2009. Wien Med Wochenschr, 159(Suppl 122): 1–34, 2009 Bekker PJ, Holloway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res, 20(12): 2275–2282, 2004 Lewiecki EM, Miller PD, McClung MR, et al.; AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res, 22(12): 1832–1841, 2007 Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone, 43(2): 222–229, 2008 Brown JP, Prince RL, Deal C, et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res, 24(1): 153–161, 2009 Cummings SR, San Martin J, McClung MR, et al. FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med, 361(8): 756–765, 2009 Smith MR, Egerdie B, Toriz NH, Feldman R, Tammela TLJ, Saad FJ, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, for the Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med, 361(8): 745–755, 2009 Lispky PE. Rheumatoid arthritis. In: Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison's principles of internal medicine, 16th edn. McGraw-Hill Companies Inc., Medical Publishing Division, New York, 2005 Saidenberg-Kermanac'h N, Bessis N, Cohen-Solal M, et al. Osteoprotegerin and inflammation. Eur Cytokine Netw, 13(2): 144–153, 2002 Cohen SB, Dore RK, Lane NE, et al.; Denosumab Rheumatoid Arthritis Study Group. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum, 58(5): 1299–1309, 2008 Dore RK, Cohen SB, Lane NE, Palmer WR, Shergy W, Zhou L, Wang H, Tsuji W, Newmark R. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis, 2009.[Epub ahead of print] Terpos E, Efstathiou E, Christoulas D, Roussou M, Katodritou E, Dimopoulos MA. RANKL inhibition: clinical implications for the management of patients with multiple myeloma and solid tumors with bone metastases. Expert Opin Biol Ther, 9(4): 465–479, 2009 Body JJ, Facon T, Coleman RE, et al. A study of the biological receptor activator of nuclear factor-kappa B ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res, 12(4): 1221–1228, 2006 Yonemori K, Fujiwara Y, Minami H, et al. Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. Cancer Sci, 99(6): 1237–1242, 2008 Fizazi K, Bosserman L, Gao G, et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol, 182(2): 509–515, 2009 Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, de Boer R, Berardi R, Gascon P, Tonkin KS, Coleman R, Paterson AH, Peterson MC, Fan M, Kinsey A, Jun S. Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol, 25(28): 4431–4437, 2007 Lipton A, Steger GG, Figueroa J, et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res, 14(20): 6690–6696, 2008 Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients wirh bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol, 27(10): 1564–1571, 2009 Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, Kim D. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat, 118(1): 81–87, 2009 Vanderkerken K, De Leenheer E, Shipman C, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res, 63(2): 287–289, 2003 Vij R, Horvath N, Spencer A, Taylor K, Vadhan-Raj S, Vescio R, Smith J, Qian Y, Yeh H, Jun S. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am J Hematol, 84(10): 650–656, 2009